The chairman of another pharmaceutical company resigned, and nearly 100 senior executives in the pharmaceutical industry left during the year

Recently, Xinbang Pharmaceutical issued an announcement stating that the board of directors of the company received a written resignation report from the chairman of the board of directors on April 13.
Due to personal reasons, Ann Huailuo applied to resign as chairman of the eighth session of the board of directors, director, convener of the strategy committee of the board of directors, Member of the Remuneration and Appraisal Committee
.
The announcement stated that after resigning from the above-mentioned positions, Ann Huailuo will serve as a consultant of Xinbang Pharmaceutical, and will no longer serve as a director, supervisor, and senior management personnel.
To ensure that the daily operations of SINBON Pharma are not affected
.
According to the data, Xinbang Pharmaceutical completed the reorganization of Guizhou Kekai Pharmaceutical in 2014, and Kekai Pharmaceutical has also become the core asset of Xinbang Pharmaceutical
.
In 2010, An Huailuo served as the general manager of Kekai Pharmaceuticals, and in 2016, he took over the position of chairman
.
It has been more than six years since then
.
According to incomplete statistics in the industry, since January 1, 2022, at least nearly 100 senior executives in the pharmaceutical industry have resigned, of which 30 executives have left in March alone, including the deputy general manager of Weili Medical and the chief executive of CStone Pharmaceuticals.
General Manager of China, General Manager of Jiangzhong Pharmaceutical, Director of Kelun Pharmaceutical,
etc.
In the pharmaceutical industry, the chairman of the board is responsible for the responsibility of the person in charge of the company, has the power to manage the company, and is responsible for the company's actions, such as presiding over shareholder meetings, convening and presiding over board meetings; checking the implementation of board resolutions and reporting to the board
.
In recent years, the changes in the pharmaceutical market have accelerated, and the accompanying executive departures have also become frequent
.
Judging from the resignation information disclosed by major pharmaceutical companies, in addition to Xinbang Pharmaceutical, there are also many chairman of pharmaceutical companies who only resigned during the year
.
For example, on March 29, Hainan Haiyao announced that the board of directors of the company received a written resignation application report from Chairman Pan Dazhong on March 26, 2022.
Mr.
Pan Dazhong was originally scheduled to serve until March 24, 2023.
Reasons to apply for resignation as director, chairman of the board, convener of the strategy committee of the board of directors and member of the nomination committee
.
After his resignation, Mr.
Pan Dazhong will not hold any position in the company, and the above resignation report will take effect from the date it is delivered to the board of directors
.
On March 11, Heavy Pharmaceutical Holdings announced that Liu Shaoyun had applied to resign as the company's chairman, director, member and convener of the strategic development and investment committee of the board of directors, and member of the nomination committee of the board of directors due to personal reasons
.
After Liu Shaoyun resigned from the above-mentioned positions, he took up a first-level professional position in the company.
The above-mentioned resignation report took effect from the date it was delivered to the board of directors
.
On March 4, Fangsheng Pharmaceutical announced that due to personal reasons, Mr.
Zhang Qinghua applied for his resignation as the company's chairman (legal representative), director, director of the strategic development committee of the board of directors and general manager
.
The resignation report submitted by him will take effect from the date it is delivered to the board of directors of the company.
After resignation, Mr.
Zhang Qinghua will still hold other positions in the company
.
On the evening of January 10, Dong’e Ejiao issued an announcement that the company’s board of directors recently received a written resignation report submitted by chairman Han Yuewei.
Due to changes in job content, Han Yuewei applied to resign as chairman and director of the company’s tenth board of directors, and resigned at the same time.
Chairman of the Strategy Committee of the 10th Board of Directors of the Company
.
After resigning, Han Yuewei no longer holds any positions in the company
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.